(FOREMOST) Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis
This study aims to explore the efficacy of the drug Apremilast in treating early stages of Psoriatic arthritis (PsA) with limited joint involvement. Apremilast currently is used as an effective treatment for PsA at later stages of disease activity.
This study will determine whether the drug is also effective at preventing joint involvement and further progression of the disease.
Patients who have a recent diagnosis of PsA (2 years or less) that are interested in participating in the study are encouraged to contact the study team to see if they qualify.
- 18 years and older
- Disease duration since diagnosis ≥ 3 months and ≤ 24 months as based on the Classification Criteria for Psoriatic Arthritis (CASPAR)
- SJC AND TJC must be >1 and ≤ 4
- Stable doses of protocol-allowed PsA medications
- General good health (except for psoriatic arthritis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories. (Note: The definition of good health means a subject does not have uncontrolled significant comorbid conditions).
- Comply with protocol-required contraception measures
Additional inclusion and exclusion criteria apply.
Principal InvestigatorMichael R Bubb, M.D.
Begin a new search for other research studies
Studies listed on this site have been approved by a UF Institutional Review Board (IRB), which works to ensure the welfare and rights of research participants as required by federal regulations. Study listings are provided by the UF Clinical and Translational Science Institute in collaboration with UF research teams and the UF IRBs.